sb-509
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2006 (NCT00406458)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Androgen ReceptorINHIBITOR
AR inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- sb-509
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01079325 | Phase 2 | Nov 1, 2009 | Juvenile Diabetes Research Foundation, Sangamo BioSciences |
| NCT00748501 | Phase 2 | Sep 1, 2008 | Sangamo BioSciences |
| NCT00665145 | Phase 2 | Jan 1, 2008 | Sangamo BioSciences |
| NCT00476931 | Phase 2 | May 1, 2007 | Sangamo BioSciences |
| NCT00406458 | Phase 2 | Nov 1, 2006 | Juvenile Diabetes Research Foundation, Sangamo BioSciences |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sangamo BioSciences | For profit | 5 | 5 | 1 | 2006 |
| Juvenile Diabetes Research Foundation | Academic/Hospital | 2 | 0 | 1 | 2006 |
2 organizations
Page 1 / 1